WINNIPEG, MB, Sept. 8, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV:WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Barbadian subsidiary, Waverley Pharma International Inc, has signed a term sheet with Reliance Life Sciences Private Limited ("RLS") that would give the Company the exclusive right, upon entering into a definitive agreement with RLS, to commercialize six additional generic oncology products in the United States. RLS will manufacture and supply the finished products and Waverley Pharma will be responsible for filing the Abbreviated New Drug Application (ANDA) for each product with the United States Food and Drug Administration. The brands represented by these six generic products, referred to by the Company as WAV-103, WAV-104, WAV-105, WAV-106, WAV-107 and WAV-108, had combined sales of more than $3 billion USD in 2019.
"We are delighted to continue our strong relationship with Reliance Life Sciences with the addition of these six products to our expanding generic oncology portfolio", stated Waverley Pharma's CEO, Larry Thiessen.